-
Mashup Score: 0Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus - 2 year(s) ago
Objectives Numerous case reports have referred to new onset or flare of SLE after SARS-CoV-2 messenger RNA (mRNA) vaccines. Several observational studies showed that the short-term flare rate of SLE after SARS-CoV-2 vaccination is low. However, well-controlled clinical surveys are unavailable and the medium-term impact of the SARS-CoV-2 mRNA vaccines against the flare of SLE is uncertain….
Source: Lupus Science & MedicineCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study - 2 year(s) ago
Objective To evaluate safety, pharmacokinetics, pharmacodynamics and efficacy of iberdomide in patients with SLE. Iberdomide is a high-affinity cereblon ligand that targets the hematopoietic transcription factors Ikaros and Aiolos for proteasomal degradation. Methods A 12-week, multicentre, double-blind, placebo-controlled, dose-escalation study in active SLE was followed by a 2-year, open-label…
Source: Lupus Science & MedicineCategories: Latest Headlines, RheumatologyTweet-
Recommended reading: Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study #ACR22 https://t.co/dO9X3SzlC9
-
-
Mashup Score: 0Top cited articles - Lupus Science & Medicine - 2 year(s) ago
Discover and read the most cited articles from Lupus Science and Medicine over the last 2 years.
Source: Lupus Science & MedicineCategories: Latest Headlines, RheumatologyTweet-
We've made brought together our top cited articles on one page to keep it easy for you #ACR22 https://t.co/StAkCiS6Gb
-
-
Mashup Score: 3
Objective Urine proteomic approaches have shown promise in identifying biological pathways in lupus nephritis (LN) which are not captured on renal histopathology or by measurement of proteinuria alone. We investigated how the urine proteome changes with treatment response and with belimumab therapy. Methods Urine samples from 54 Belimumab International Systemic Lupus Erythematosus–Lupus…
Source: Lupus Science & MedicineCategories: Healthcare Professionals, Latest HeadlinesTweet-
Urine proteomics on 54 SLE pts in the Belimumab–Lupus Nephritis trial, compared responders (n 31) v non-responders (n 22), on BEL or SOC. Reduction in urinary CD163 was strongly associated with complete renal response @wk52 & CD23 @wk24 https://t.co/PrXaJq6h0E https://t.co/IWREF9VmZ8
-
-
Mashup Score: 0
Objective Urine proteomic approaches have shown promise in identifying biological pathways in lupus nephritis (LN) which are not captured on renal histopathology or by measurement of proteinuria alone. We investigated how the urine proteome changes with treatment response and with belimumab therapy. Methods Urine samples from 54 Belimumab International Systemic Lupus Erythematosus–Lupus…
Source: Lupus Science & MedicineCategories: Latest Headlines, RheumatologyTweet-
1st study to examine the effect of #belimumab, on the #urine proteome in LN: data shows #shifts in profiles are seen with belimumab therapy, with results suggesting that future studies modulation of CD23-mediated immune enhancement pathways in LN response. https://t.co/mMUeiPiRjN
-
-
Mashup Score: 3
Objective Urine proteomic approaches have shown promise in identifying biological pathways in lupus nephritis (LN) which are not captured on renal histopathology or by measurement of proteinuria alone. We investigated how the urine proteome changes with treatment response and with belimumab therapy. Methods Urine samples from 54 Belimumab International Systemic Lupus Erythematosus–Lupus…
Source: Lupus Science & MedicineCategories: Healthcare Professionals, Latest HeadlinesTweet-
Urine proteomics on 54 SLE pts in the Belimumab–Lupus Nephritis trial, compared responders (n 31) v non-responders (n 22), on BEL or SOC. Reduction in urinary CD163 was strongly associated with complete renal response @wk52 & CD23 @wk24 https://t.co/Rais8fKame https://t.co/F3B9W7u7VO
-
-
Mashup Score: 2
Objective It is still unclear how glucocorticoids (GCs) affect the long-term clinical course of patients with SLE. The objective of this study is to explore the factors associated with GC-free treatment status. Methods Using data from the lupus registry of nationwide institutions, GC dose at registration was compared between short, middle and long disease durations of <5, 5–20 and ≥20 years,...
Source: Lupus Science & MedicineCategories: Latest Headlines, RheumatologyTweet-
#Outcomes New #research shows that #glucocorticoids use is avoidable in the #long-term care of #patients with #SLE. https://t.co/8h6v4ocJs3
-
-
Mashup Score: 0CD4+ T-cell cooperation promoted pathogenic function of activated naïve B cells of patients with SLE - 2 year(s) ago
Objective To explore cooperation between activated naïve (aNAV) B cells and CD4+ T cells in the pathogenesis of SLE through autoantibody production, T-cell differentiation and inflammatory cytokine secretion. Methods Peripheral blood mononuclear cell samples were obtained from 31 patients with SLE and used to characterise phenotype of aNAV B cells (n=14) and measured the phosphorylation of…
Source: Lupus Science & MedicineCategories: Latest Headlines, RheumatologyTweet-
#immunology Study show that #Bcells, w/ upregulated #Tcell #costimulatory & FCRL5 molecules, responded to BCR ligation leading to the activation of PLCγ2 #signaling. BCR & #TLR7/TLR8 signals, promoted #CD4+ Tcell proliferation & polarization to #Th2 &#Th17 https://t.co/uRTsRMEEgA
-
-
Mashup Score: 2
Objective Urine proteomic approaches have shown promise in identifying biological pathways in lupus nephritis (LN) which are not captured on renal histopathology or by measurement of proteinuria alone. We investigated how the urine proteome changes with treatment response and with belimumab therapy. Methods Urine samples from 54 Belimumab International Systemic Lupus Erythematosus–Lupus…
Source: Lupus Science & MedicineCategories: Latest Headlines, RheumatologyTweet-
1st study to examine the effect of #belimumab, on the #urine proteome in LN: data shows #shifts in profiles are seen with belimumab therapy, with results suggesting that future studies modulation of CD23-mediated immune enhancement pathways in LN response. https://t.co/mMUeiPiRjN
-
-
Mashup Score: 0
Objective It is still unclear how glucocorticoids (GCs) affect the long-term clinical course of patients with SLE. The objective of this study is to explore the factors associated with GC-free treatment status. Methods Using data from the lupus registry of nationwide institutions, GC dose at registration was compared between short, middle and long disease durations of <5, 5–20 and ≥20 years,...
Source: Lupus Science & MedicineCategories: Latest Headlines, RheumatologyTweet-
#Outcomes New #research shows that #glucocorticoids use is avoidable in the #long-term care of #patients with #SLE. https://t.co/8h6v4odhhB
-
Medium-term impact of the SARSCoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus https://t.co/r8B8fqZXdY #ACR22